Abstract
Background: Of the >140 anticancer drugs approved since 1940 and available for clinical application, >60% can be traced to a natural product. Of the small molecules among them, 67% are natural in origin. Nanocarriers can be effective anticancer drug delivery systems for preventing and treating cancers. It has been demonstrated that nanoparticles used for drug therapy provide some advantages over conventional formulations, including increased solubility, enhanced storage stability, improved permeability and bioavailability, prolonged half-life, tissue targeting, and minimal side effects. Methods: In recent years, the concept of using nanoparticles as the carriers of natural products or herbal drugs has attracted increasing attention. This review highlights recent developments using nanomedical approaches for natural product delivery. Results: We systematically introduce the concepts and amelioration mechanisms of the nanomedical techniques for natural product cancer therapy. These modalities are useful in the therapy incorporating a wide variety of natural products for treating brain, lung, breast, and colorectal cancers. The nanosystems for biomedicine can be categorized into three groups: polymeric, lipid, and metallic nanoparticles. All of these have been employed as anticancer carriers for natural products. This review describes various nanocarriers loaded with natural compounds for passive or active targeting of tumors. Conclusion: The nanomedicine research data for phytomedicine cancer remedies suggest a way forward for generating advances in chemotherapy.
Keywords: Natural product, cancer, nanomedicine, nanoparticle, drug delivery.
Current Pharmaceutical Design
Title:Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Volume: 22 Issue: 27
Author(s): Ibrahim A. Aljuffali, Chia-Lang Fang, Chun-Han Chen and Jia-You Fang
Affiliation:
Keywords: Natural product, cancer, nanomedicine, nanoparticle, drug delivery.
Abstract: Background: Of the >140 anticancer drugs approved since 1940 and available for clinical application, >60% can be traced to a natural product. Of the small molecules among them, 67% are natural in origin. Nanocarriers can be effective anticancer drug delivery systems for preventing and treating cancers. It has been demonstrated that nanoparticles used for drug therapy provide some advantages over conventional formulations, including increased solubility, enhanced storage stability, improved permeability and bioavailability, prolonged half-life, tissue targeting, and minimal side effects. Methods: In recent years, the concept of using nanoparticles as the carriers of natural products or herbal drugs has attracted increasing attention. This review highlights recent developments using nanomedical approaches for natural product delivery. Results: We systematically introduce the concepts and amelioration mechanisms of the nanomedical techniques for natural product cancer therapy. These modalities are useful in the therapy incorporating a wide variety of natural products for treating brain, lung, breast, and colorectal cancers. The nanosystems for biomedicine can be categorized into three groups: polymeric, lipid, and metallic nanoparticles. All of these have been employed as anticancer carriers for natural products. This review describes various nanocarriers loaded with natural compounds for passive or active targeting of tumors. Conclusion: The nanomedicine research data for phytomedicine cancer remedies suggest a way forward for generating advances in chemotherapy.
Export Options
About this article
Cite this article as:
Aljuffali A. Ibrahim, Fang Chia-Lang, Chen Chun-Han and Fang Jia-You, Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers, Current Pharmaceutical Design 2016; 22 (27) . https://dx.doi.org/10.2174/1381612822666160620072539
DOI https://dx.doi.org/10.2174/1381612822666160620072539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Therapeutic Potential of HDAC Inhibitors in the Treatment of Cardiac Diseases: A Short Review
Current Drug Targets Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors
Current Drug Targets <i>In vitro</i> Antiproliferative Properties of Lipophililic-Acid Chelating Fluoroquinolones and TriazoloFluoroquinolones with 7-dihaloanilinosubstitution
Anti-Cancer Agents in Medicinal Chemistry Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Prospective Role of MicroRNAs in Depression
Current Medicinal Chemistry Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Acid Sphingomyelinase/Ceramide Pathway: Biomedical Significance and Mechanisms of Regulation
Current Molecular Medicine Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer
Current Drug Delivery Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Current Chemical Biology Identification of HDACs Inhibitor E14 Metabolites Appeared in Rat Plasma, Feces and Urine by UPLC-QTOF-MS/MS
Current Pharmaceutical Analysis